UA79440C2 - Аналоги гормону, що вивільнюють гормон росту людини, спосіб їх одержання, фармацевтична композиція та спосіб лікування - Google Patents

Аналоги гормону, що вивільнюють гормон росту людини, спосіб їх одержання, фармацевтична композиція та спосіб лікування Download PDF

Info

Publication number: UA79440C2
Authority: UA; Ukraine
Prior art keywords: aia; sar; pago; zeg; azr
Prior art date: 2001-10-31

Application number

UA20040504092A

Other languages

English (en)

Russian (ru)

Ukrainian (uk)

Inventor

Ян Іздєбскі

Данута Кунце

Алісья Орловська

Єва Вітковська

Веслав Шелеєвскі

Анджей Кутнер

Кжиштоф Банковські

Ельзбета Фрацкевич

Original Assignee

Інститут Фармацевтични

Заклади Фармацевтичне Польфарма С.А.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-31

Filing date

2002-10-30

Publication date

2007-06-25

2002-10-30 Application filed by Інститут Фармацевтични, Заклади Фармацевтичне Польфарма С.А. filed Critical Інститут Фармацевтични

2007-06-25 Publication of UA79440C2 publication Critical patent/UA79440C2/uk

Links

238000000034 method Methods 0.000 title claims abstract description 24
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
-1 method of production Substances 0.000 title claims description 11
239000003488 releasing hormone Substances 0.000 title abstract description 3
102000002265 Human Growth Hormone Human genes 0.000 title description 5
108010000521 Human Growth Hormone Proteins 0.000 title description 5
239000000854 Human Growth Hormone Substances 0.000 title description 5
238000004519 manufacturing process Methods 0.000 title description 2
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 67
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 31
150000003839 salts Chemical class 0.000 claims abstract description 15
102000018997 Growth Hormone Human genes 0.000 claims abstract description 13
108010051696 Growth Hormone Proteins 0.000 claims abstract description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
239000000122 growth hormone Substances 0.000 claims abstract description 12
206010056438 Growth hormone deficiency Diseases 0.000 claims abstract 2
239000011347 resin Substances 0.000 claims description 21
229920005989 resin Polymers 0.000 claims description 21
125000003275 alpha amino acid group Chemical group 0.000 claims description 12
229920000642 polymer Polymers 0.000 claims description 10
238000006243 chemical reaction Methods 0.000 claims description 8
238000004128 high performance liquid chromatography Methods 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 7
PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims description 5
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 5
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims description 5
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 5
101710142969 Somatoliberin Proteins 0.000 claims description 5
125000003277 amino group Chemical group 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
238000010511 deprotection reaction Methods 0.000 claims description 5
229910000040 hydrogen fluoride Inorganic materials 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
230000003993 interaction Effects 0.000 claims description 4
238000010532 solid phase synthesis reaction Methods 0.000 claims description 4
OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 3
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 3
238000003776 cleavage reaction Methods 0.000 claims description 3
238000000746 purification Methods 0.000 claims description 3
230000007017 scission Effects 0.000 claims description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
239000003668 hormone analog Substances 0.000 claims 1
150000001413 amino acids Chemical group 0.000 abstract description 15
229940088597 hormone Drugs 0.000 abstract description 10
239000005556 hormone Substances 0.000 abstract description 10
239000004480 active ingredient Substances 0.000 abstract description 4
ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 3
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
150000001875 compounds Chemical class 0.000 description 20
239000000243 solution Substances 0.000 description 19
229940024606 amino acid Drugs 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 15
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
208000035475 disorder Diseases 0.000 description 9
239000000126 substance Substances 0.000 description 9
241000700159 Rattus Species 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
230000037396 body weight Effects 0.000 description 7
230000000694 effects Effects 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
125000001151 peptidyl group Chemical group 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
101000825742 Homo sapiens Somatoliberin Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
238000009472 formulation Methods 0.000 description 5
102000045304 human GHRH Human genes 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
102000009151 Luteinizing Hormone Human genes 0.000 description 3
108010073521 Luteinizing Hormone Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102000006877 Pituitary Hormones Human genes 0.000 description 3
108010047386 Pituitary Hormones Proteins 0.000 description 3
108010057464 Prolactin Proteins 0.000 description 3
102000003946 Prolactin Human genes 0.000 description 3
102000011923 Thyrotropin Human genes 0.000 description 3
108010061174 Thyrotropin Proteins 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000002585 base Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
238000007429 general method Methods 0.000 description 3
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
239000000960 hypophysis hormone Substances 0.000 description 3
239000007943 implant Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 3
230000002265 prevention Effects 0.000 description 3
229940097325 prolactin Drugs 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
229960000874 thyrotropin Drugs 0.000 description 3
230000001748 thyrotropin Effects 0.000 description 3
UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
150000001718 carbodiimides Chemical class 0.000 description 2
229940125904 compound 1 Drugs 0.000 description 2
238000001514 detection method Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000007515 enzymatic degradation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
229960003299 ketamine Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
241000402754 Erythranthe moschata Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
102000015611 Hypothalamic Hormones Human genes 0.000 description 1
108010024118 Hypothalamic Hormones Proteins 0.000 description 1
238000001276 Kolmogorov–Smirnov test Methods 0.000 description 1
238000012313 Kruskal-Wallis test Methods 0.000 description 1
QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
108010053803 Sermorelin Proteins 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
208000020221 Short stature Diseases 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000256856 Vespidae Species 0.000 description 1
241000458243 Viana Species 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000003862 amino acid derivatives Chemical class 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000002152 aqueous-organic solution Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
235000021028 berry Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
102000038379 digestive enzymes Human genes 0.000 description 1
108091007734 digestive enzymes Proteins 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
239000000601 hypothalamic hormone Substances 0.000 description 1
229940043650 hypothalamic hormone Drugs 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical group CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
230000000720 neurosecretory effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
230000001175 peptic effect Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
VBQCHPIMZGQLAZ-UHFFFAOYSA-N phosphorane Chemical class [PH5] VBQCHPIMZGQLAZ-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000011253 protective coating Substances 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000006340 racemization Effects 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000003578 releasing effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
BVLCEKWPOSAKSZ-YQMCHIOTSA-N sermorelin acetate Chemical compound CC(O)=O.C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 BVLCEKWPOSAKSZ-YQMCHIOTSA-N 0.000 description 1
229960003137 sermorelin acetate Drugs 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
231100000075 skin burn Toxicity 0.000 description 1
239000007787 solid Substances 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
230000001810 trypsinlike Effects 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

UA20040504092A 2001-10-31 2002-10-30 Аналоги гормону, що вивільнюють гормон росту людини, спосіб їх одержання, фармацевтична композиція та спосіб лікування UA79440C2 (uk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PL350463A PL195917B1 (pl)	2001-10-31	2001-10-31	Nowe peptydy - analogi ludzkiego hormonu uwalniającego hormon wzrostu
PCT/PL2002/000080 WO2003037928A2 (en)	2001-10-31	2002-10-30	Analogs of human growth hormone-releasing hormone, their preparation and use

Publications (1)

Publication Number	Publication Date
UA79440C2 true UA79440C2 (uk)	2007-06-25

Family

ID=20079564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040504092A UA79440C2 (uk)	2001-10-31	2002-10-30	Аналоги гормону, що вивільнюють гормон росту людини, спосіб їх одержання, фармацевтична композиція та спосіб лікування

Country Status (14)

Country	Link
US (1)	US7928063B2 (pl)
EP (1)	EP1442059B1 (pl)
JP (1)	JP4401170B2 (pl)
AT (1)	ATE353917T1 (pl)
AU (1)	AU2002351536A1 (pl)
CA (1)	CA2465667C (pl)
DE (1)	DE60218199T2 (pl)
EA (1)	EA007841B1 (pl)
ES (1)	ES2282494T3 (pl)
HU (1)	HU229220B1 (pl)
PL (1)	PL195917B1 (pl)
SI (1)	SI1442059T1 (pl)
UA (1)	UA79440C2 (pl)
WO (1)	WO2003037928A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060128615A1 (en) *	2002-09-18	2006-06-15	Pierrette Gaudreau	Ghrh analogues
WO2011153491A2 (en)	2010-06-03	2011-12-08	University Of Miami	Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
WO2012037519A2 (en) *	2010-09-16	2012-03-22	University Of Miami	Acceleration of wound healing by growth hormone releasing hormone and its agonists
WO2012068187A1 (en) *	2010-11-19	2012-05-24	Merck Sharp & Dohme Corp.	Poly(amide) polymers for the delivery of oligonucleotides
EP2768518A4 (en) *	2011-10-18	2015-05-27	Aileron Therapeutics Inc	PEPTIDOMIMETIC MACROCYCLES
US9079974B2 (en) *	2011-12-21	2015-07-14	The University Of Miami	GH-RH analogs with potent agonistic effects
US9855312B2 (en)	2012-12-21	2018-01-02	University Of Miami	GHRH agonists for the treatment of ischemic disorders
WO2014100816A2 (en)	2012-12-21	2014-06-26	University Of Miami	Ghrh agonists for islet cell transplantation and function and the treatment of diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5416073A (en) *	1983-08-10	1995-05-16	The Adminstrators Of The Tulane Educational Fund	Growth hormone-releasing peptides and method of treating animals, therewith
US5792747A (en) *	1995-01-24	1998-08-11	The Administrators Of The Tulane Educational Fund	Highly potent agonists of growth hormone releasing hormone
US6072075A (en) *	1997-05-22	2000-06-06	The Regents Of The University Of California	Guanidinylation reagents

2001
- 2001-10-31 PL PL350463A patent/PL195917B1/pl unknown
2002
- 2002-10-30 AT AT02786274T patent/ATE353917T1/de not_active IP Right Cessation
- 2002-10-30 UA UA20040504092A patent/UA79440C2/uk unknown
- 2002-10-30 EP EP02786274A patent/EP1442059B1/en not_active Expired - Lifetime
- 2002-10-30 SI SI200230531T patent/SI1442059T1/sl unknown
- 2002-10-30 CA CA2465667A patent/CA2465667C/en not_active Expired - Fee Related
- 2002-10-30 US US10/494,218 patent/US7928063B2/en not_active Expired - Fee Related
- 2002-10-30 AU AU2002351536A patent/AU2002351536A1/en not_active Abandoned
- 2002-10-30 ES ES02786274T patent/ES2282494T3/es not_active Expired - Lifetime
- 2002-10-30 WO PCT/PL2002/000080 patent/WO2003037928A2/en not_active Ceased
- 2002-10-30 EA EA200400603A patent/EA007841B1/ru not_active IP Right Cessation
- 2002-10-30 JP JP2003540209A patent/JP4401170B2/ja not_active Expired - Fee Related
- 2002-10-30 DE DE60218199T patent/DE60218199T2/de not_active Expired - Lifetime
- 2002-10-30 HU HU0401589A patent/HU229220B1/hu not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2282494T3 (es)	2007-10-16
HU229220B1 (hu)	2013-09-30
EA007841B1 (ru)	2007-02-27
CA2465667A1 (en)	2003-05-08
ATE353917T1 (de)	2007-03-15
PL195917B1 (pl)	2007-11-30
EP1442059A2 (en)	2004-08-04
HUP0401589A2 (hu)	2004-11-29
WO2003037928A2 (en)	2003-05-08
JP4401170B2 (ja)	2010-01-20
HUP0401589A3 (en)	2005-11-28
US7928063B2 (en)	2011-04-19
CA2465667C (en)	2011-03-08
WO2003037928A3 (en)	2004-03-04
AU2002351536A1 (en)	2003-05-12
SI1442059T1 (sl)	2007-08-31
PL350463A1 (en)	2003-05-05
EP1442059B1 (en)	2007-02-14
DE60218199D1 (de)	2007-03-29
JP2005517633A (ja)	2005-06-16
DE60218199T2 (de)	2007-11-22
EA200400603A1 (ru)	2006-06-30
US20060172927A1 (en)	2006-08-03

Publication	Publication Date	Title
AU746461B2 (en)	2002-05-02	Peptide parathyroid hormone analogs
FI92326C (fi)	1994-10-25	LHRH:n nonapeptidi- ja dekapeptidianalogeja, jotka ovat käyttökelpoisia LHRH:n antagonisteina
HU217636B (hu)	2000-03-28	Szomatosztatin analógok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUT64367A (en)	1993-12-28	Method for producing glucagon-like peptides and insulino-tropine derivatives as well as medical preparatives containing said compounds
HU213098B (en)	1997-02-28	Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components
EP0736038A1 (en)	1996-10-09	Compounds with growth hormone releasing properties
US6211151B1 (en)	2001-04-03	Peptides with organo-protective activity, a process for preparation thereof and their use in therapy
EP1133522B1 (en)	2006-07-05	Antagonistic analogs of gh-rh inhibiting igf-i and -ii
HU186729B (en)	1985-09-30	Process for the production of biologycally active pentapeptide-derivatives
JPH085913B2 (ja)	1996-01-24	治療用ソマトスタチン同族体
EP1442059B1 (en)	2007-02-14	Analogs of human growth hormone-releasing hormone, their preparation and use
Feurle et al.	1996	Neurokinetic and myokinetic effects of the peptide xenin on the motility of the small and large intestine of guinea pig.
US5633263A (en)	1997-05-27	Linear somatostatin analogs
CA1338302C (en)	1996-04-30	Therapeutic octapeptide somatostatin analogs
HU215121B (hu)	1998-09-28	Eljárás vazotocinszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények előállítására
CA2405724C (en)	2010-09-07	Substance p analogs for the treatment of cancer
CZ55496A3 (en)	1996-08-14	Tripeptides, processes of their preparation, their use, pharmaceutical compositions and diagnostic agents based thereon
ZA200302505B (en)	2005-05-30	Urotensin-II agonists and antagonists.
JPH09502427A (ja)	1997-03-11	オキシトシン拮抗薬活性を示すペプチド
Abiko et al.	2001	Syntheses of Cholecystokin in (Cck) Fragment Analogues (26-33) and Comparative Effect on Decreased Feeding in Rats by Cck Fragment (26-33)
CN116970040A (zh)	2023-10-31	一类通过酰胺键成环的阿片类多靶点环六肽分子及其制备和应用
Abiko et al.	2001	Syntheses of neurotensin (nt) analogues and their comparative anorectic effect on food intake in rats
EP0200512A2 (en)	1986-11-05	Peptides and their use in therapy
CA2405689A1 (en)	2001-08-23	Vasoactive intestinal peptide analogs